0001809122 2023-01-01 2023-06-30 0001809122 cvac:DietmarHoppMember 2020-08-01 2020-08-31 0001809122 cvac:IfrsCashAndCashEquivalentsMember ifrs-full:CurrencyRiskMember currency:USD 2023-06-30 0001809122 cvac:IfrsCashAndCashEquivalentsMember ifrs-full:CurrencyRiskMember currency:CHF 2023-06-30 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-04-01 2023-06-30 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-04-01 2023-06-30 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-04-01 2023-06-30 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2023-04-01 2023-06-30 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-01-01 2023-06-30 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-01-01 2023-06-30 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-01-01 2023-06-30 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-04-01 2022-06-30 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-04-01 2022-06-30 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-04-01 2022-06-30 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2022-04-01 2022-06-30 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-06-30 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-06-30 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-06-30 0001809122 country:NL cvac:GenmabMember 2023-04-01 2023-06-30 0001809122 country:CH cvac:CrisprMember 2023-04-01 2023-06-30 0001809122 country:BE cvac:GlaxosmithklineMember 2023-04-01 2023-06-30 0001809122 country:NL cvac:GenmabMember 2023-01-01 2023-06-30 0001809122 country:CH cvac:CrisprMember 2023-01-01 2023-06-30 0001809122 country:BE cvac:GlaxosmithklineMember 2023-01-01 2023-06-30 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2023-01-01 2023-06-30 0001809122 cvac:ResearchAndDevelopmentServicesMember 2023-01-01 2023-06-30 0001809122 cvac:MilestoneRevenuesMember 2023-01-01 2023-06-30 0001809122 cvac:IfrsProductMember 2023-01-01 2023-06-30 0001809122 country:NL cvac:GenmabMember 2022-04-01 2022-06-30 0001809122 country:CH cvac:CrisprMember 2022-04-01 2022-06-30 0001809122 country:BE cvac:GlaxosmithklineMember 2022-04-01 2022-06-30 0001809122 country:NL cvac:GenmabMember 2022-01-01 2022-06-30 0001809122 country:CH cvac:CrisprMember 2022-01-01 2022-06-30 0001809122 country:BE cvac:GlaxosmithklineMember 2022-01-01 2022-06-30 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-06-30 0001809122 cvac:ResearchAndDevelopmentServicesMember 2022-01-01 2022-06-30 0001809122 cvac:MilestoneRevenuesMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsProductMember 2022-01-01 2022-06-30 0001809122 cvac:BepharbelManufacturingS.aMember 2021-01-01 2021-12-31 0001809122 cvac:VincentStphenneMember 2023-01-01 2023-06-30 0001809122 cvac:BaronJeanStephenneMember 2023-01-01 2023-06-30 0001809122 cvac:DietmarHoppMember 2020-08-31 0001809122 ifrs-full:PreferenceSharesMember 2023-06-30 0001809122 ifrs-full:OrdinarySharesMember 2023-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ThenChiefExecutiveOfficerMember 2023-04-01 2023-04-01 0001809122 cvac:LongTermIncentivePlanMember cvac:KeyEmployeesMember 2022-04-01 2022-04-01 0001809122 cvac:LongTermIncentivePlanMember cvac:ExecutiveBoardMembersMember 2022-03-01 2022-03-01 0001809122 cvac:LongTermIncentivePlanMember cvac:KeyEmployeesMember 2022-01-01 2022-01-01 0001809122 cvac:LongTermIncentivePlanMember srt:ChiefOperatingOfficerMember 2021-07-01 2021-07-01 0001809122 cvac:LongTermIncentivePlanMember cvac:KeyEmployeesMember 2021-03-01 2021-03-01 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember 2020-12-01 2020-12-01 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefScientificOfficerMember 2020-11-16 2020-11-16 0001809122 cvac:VirtualSharesProgramIiMember 2023-04-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanMember srt:ChiefOperatingOfficerMember 2023-01-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ThenChiefExecutiveOfficerMember 2023-01-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:KeyEmployeesMember 2023-01-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ExecutiveBoardMembersMember 2023-01-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember 2023-01-01 2023-06-30 0001809122 cvac:VirtualSharesProgramIiMember 2023-01-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefScientificOfficerMember 2022-01-01 2022-12-31 0001809122 cvac:SupervisoryBoardMembersMember 2023-03-31 2023-03-31 0001809122 cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember 2023-03-31 2023-03-31 0001809122 cvac:KeyEmployeesMember 2022-11-30 2022-11-30 0001809122 cvac:FormerFrameEmployeesMember 2022-07-01 2022-07-01 0001809122 cvac:SupervisoryBoardMembersMember 2022-06-22 2022-06-22 0001809122 cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember 2022-06-22 2022-06-22 0001809122 cvac:ChiefBusinessOfficerMember 2022-01-31 2022-01-31 0001809122 srt:ChiefOperatingOfficerMember 2022-01-01 2022-01-01 0001809122 cvac:LongTermIncentivePlanMember cvac:SupervisoryBoardMembersMember 2021-06-24 2021-06-24 0001809122 srt:ChiefOperatingOfficerMember 2022-01-31 2022-01-31 0001809122 cvac:LongTermIncentivePlanMember cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember 2021-12-23 2021-12-23 0001809122 ifrs-full:IssuedCapitalMember 2022-01-01 2022-06-30 0001809122 ifrs-full:RetainedEarningsMember 2023-06-30 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-06-30 0001809122 ifrs-full:IssuedCapitalMember 2023-06-30 0001809122 ifrs-full:CapitalReserveMember 2023-06-30 0001809122 ifrs-full:TreasurySharesMember 2022-12-31 0001809122 ifrs-full:RetainedEarningsMember 2022-12-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-12-31 0001809122 ifrs-full:IssuedCapitalMember 2022-12-31 0001809122 ifrs-full:CapitalReserveMember 2022-12-31 0001809122 ifrs-full:TreasurySharesMember 2022-06-30 0001809122 ifrs-full:RetainedEarningsMember 2022-06-30 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-06-30 0001809122 ifrs-full:IssuedCapitalMember 2022-06-30 0001809122 ifrs-full:CapitalReserveMember 2022-06-30 0001809122 ifrs-full:TreasurySharesMember 2021-12-31 0001809122 ifrs-full:RetainedEarningsMember 2021-12-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001809122 ifrs-full:IssuedCapitalMember 2021-12-31 0001809122 ifrs-full:CapitalReserveMember 2021-12-31 0001809122 ifrs-full:RetainedEarningsMember 2023-01-01 2023-06-30 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-01-01 2023-06-30 0001809122 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-01-01 2022-06-30 0001809122 cvac:BepharbelManufacturingS.aMember 2022-05-01 2022-05-31 0001809122 2022-06-30 0001809122 2021-12-31 0001809122 ifrs-full:ConstructionInProgressMember 2023-01-01 2023-06-30 0001809122 cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember 2023-01-01 2023-06-30 0001809122 cvac:CompanyOwnedGmpIvFacilityMember 2023-01-01 2023-06-30 0001809122 ifrs-full:ConstructionInProgressMember 2022-01-01 2022-06-30 0001809122 cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember 2022-01-01 2022-06-30 0001809122 ifrs-full:GrossCarryingAmountMember cvac:LicensesSoftwareAndPrepaymentsMember 2023-01-01 2023-06-30 0001809122 ifrs-full:GrossCarryingAmountMember cvac:LicensesSoftwareAndPrepaymentsMember 2022-01-01 2022-06-30 0001809122 cvac:GlaxosmithklineMember ifrs-full:BottomOfRangeMember 2023-06-30 0001809122 cvac:GlaxosmithklineMember 2023-06-30 0001809122 cvac:GenmabMember 2023-06-30 0001809122 cvac:CrisprMember 2023-06-30 0001809122 cvac:GlaxosmithklineMember 2022-12-31 0001809122 cvac:GenmabMember 2022-12-31 0001809122 cvac:CrisprMember 2022-12-31 0001809122 ifrs-full:TreasurySharesMember 2023-01-01 2023-06-30 0001809122 ifrs-full:IssuedCapitalMember 2023-01-01 2023-06-30 0001809122 ifrs-full:CapitalReserveMember 2023-01-01 2023-06-30 0001809122 ifrs-full:TreasurySharesMember 2022-01-01 2022-06-30 0001809122 ifrs-full:CapitalReserveMember 2022-01-01 2022-06-30 0001809122 cvac:GlaxosmithklineMember 2021-12-31 0001809122 cvac:AtMarketOfferingProgramMember 2023-06-30 0001809122 cvac:DietmarHoppMember 2019-01-01 2019-12-31 0001809122 cvac:ClarentisSrlMember cvac:AntonyBlancMember 2023-01-01 2023-06-30 0001809122 ifrs-full:TopOfRangeMember cvac:LargestShareholderMember 2023-06-30 0001809122 ifrs-full:BottomOfRangeMember cvac:LargestShareholderMember 2023-06-30 0001809122 cvac:SellingAndDistributionExpensesMember 2023-04-01 2023-06-30 0001809122 cvac:SellingAndDistributionExpensesMember 2023-01-01 2023-06-30 0001809122 cvac:SellingAndDistributionExpensesMember 2022-04-01 2022-06-30 0001809122 cvac:SellingAndDistributionExpensesMember 2022-01-01 2022-06-30 0001809122 cvac:PatentInfringementLawsuitFilledMember 2023-08-01 2023-08-31 0001809122 2023-04-01 2023-04-30 0001809122 cvac:FormerFrameEmployeesMember 2023-06-30 2023-06-30 0001809122 cvac:KeyEmployeesMember 2023-01-01 2023-06-30 0001809122 cvac:PatentInfringementLawsuitFilledMember 2023-07-01 2023-07-31 0001809122 cvac:PatentInfringementLawsuitFilledMember 2023-05-01 2023-05-31 0001809122 2023-05-01 2023-05-31 0001809122 2022-06-01 2022-06-30 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001809122 cvac:IfrsGeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001809122 cvac:IfrsCostOfSalesMember 2023-04-01 2023-06-30 0001809122 cvac:IfrsGeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001809122 cvac:IfrsCostOfSalesMember 2023-01-01 2023-06-30 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001809122 cvac:IfrsGeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001809122 cvac:IfrsCostOfSalesMember 2022-04-01 2022-06-30 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsGeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsCostOfSalesMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001809122 2022-01-01 2022-12-31 0001809122 cvac:FollowOnPublicOfferingMember 2023-01-01 2023-03-31 0001809122 cvac:AtMarketOfferingProgramMember 2023-01-01 2023-03-31 0001809122 cvac:FollowOnPublicOfferingMember 2023-02-28 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2022-12-31 0001809122 cvac:MilestoneRevenuesMember 2023-06-30 0001809122 cvac:ClarentisSrlMember 2021-09-30 0001809122 cvac:CraigToomanMember 2023-01-01 2023-06-30 0001809122 cvac:BarkerBiomedicalGmbhMember 2023-01-01 2023-06-30 0001809122 cvac:PriorVirtualStockOptionsPlanMember 2023-04-01 2023-06-30 0001809122 cvac:NewVirtualStockOptionsPlanMember 2023-04-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanAndRestrictedStockUnitMember 2023-04-01 2023-06-30 0001809122 cvac:IfrsRestrictedStockUnitMember 2023-04-01 2023-06-30 0001809122 cvac:PriorVirtualStockOptionsPlanMember 2023-01-01 2023-06-30 0001809122 cvac:NewVirtualStockOptionsPlanMember 2023-01-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanAndRestrictedStockUnitMember 2023-01-01 2023-06-30 0001809122 cvac:IfrsRestrictedStockUnitMember 2023-01-01 2023-06-30 0001809122 cvac:PriorVirtualStockOptionsPlanMember 2022-04-01 2022-06-30 0001809122 cvac:NewVirtualStockOptionsPlanMember 2022-04-01 2022-06-30 0001809122 cvac:LongTermIncentivePlanAndRestrictedStockUnitMember 2022-04-01 2022-06-30 0001809122 cvac:IfrsRestrictedStockUnitMember 2022-04-01 2022-06-30 0001809122 cvac:PriorVirtualStockOptionsPlanMember 2022-01-01 2022-06-30 0001809122 cvac:NewVirtualStockOptionsPlanMember 2022-01-01 2022-06-30 0001809122 cvac:LongTermIncentivePlanAndRestrictedStockUnitMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsRestrictedStockUnitMember 2022-01-01 2022-06-30 0001809122 cvac:LongTermIncentivePlanMember 2023-04-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanMember 2023-01-01 2023-06-30 0001809122 cvac:LongTermIncentivePlanMember 2022-04-01 2022-06-30 0001809122 cvac:LongTermIncentivePlanMember 2022-01-01 2022-06-30 0001809122 2023-01-01 2023-03-31 0001809122 cvac:GlaxosmithklineMember 2022-01-01 2022-06-30 0001809122 2023-06-30 0001809122 2023-03-31 0001809122 2022-12-31 0001809122 2023-04-01 2023-06-30 0001809122 2022-04-01 2022-06-30 0001809122 cvac:AtMarketOfferingProgramMember 2021-09-01 2021-09-30 0001809122 2022-01-01 2022-06-30 0001809122 cvac:FollowOnPublicOfferingMember 2023-02-01 2023-02-28 0001809122 cvac:MilestoneRevenuesMember 2022-04-01 2022-06-30 iso4217:CHF iso4217:EUR iso4217:USD xbrli:shares iso4217:USD xbrli:shares cvac:item xbrli:pure cvac:loan iso4217:EUR xbrli:shares cvac:Option

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 6-K

​

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

​

For the month of August, 2023

Commission File Number: 001-39446

​

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

​

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

​

Form 20-F | ☒ |  | Form 40-F | ☐

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

​

Yes | ☐ |  | No | ☒

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

​

Yes | ☐ |  | No | ☒

​

​

​

​

This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is being furnished by CureVac N.V. ("CureVac") to the Securities and Exchange Commission (the “SEC”) for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac’s financial results and business updates as of June 30, 2023 and for the three and six month periods ended June 30, 2023 and 2022; and (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management’s Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac's financial condition and results of operations as of June 30, 2023 and for the six month periods ended June 30, 2023 and 2022.

The information included in this Form 6-K (including Exhibits 99.1 and 99.2) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​ | CUREVAC N.V.
​ | ​ | ​
​ | By: | /s/Alexander Zehnder
​ | ​ | Chief Executive Officer
​ | ​ | ​
​ | ​ | ​
Date: August 17, 2023 | ​ | ​

​

​

​

EXHIBIT INDEX

​

EXHIBIT NO. |  | DESCRIPTION
99.1 |  | Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2023 and for three and six months ended June 30, 2023 and 2022
99.2 | ​ | Management’s Discussion and Analysis of Financial Condition and Results of Operations

​

​